-
Jonathan
Angel,
Jonathan
Angel,
K.
Parato,
K.
Parato,
Ashok
Kumar,
S.
Kravcik,
Andrew
Badley,
Andrew
Badley,
Carole
Fex,
Deborah
Ashby,
Eugene
Sun,
D.
Cameron,
D.
Cameron
(2001)
Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.
The Journal of infectious diseases, 183 4
-
E.
Seminari,
F.
Maggiolo,
P.
Villani,
F.
Suter,
A.
Pan,
M.
Regazzi,
S.
Paolucci,
F.
Baldanti,
C.
Tinelli,
R.
Maserati
(1999)
Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.
Journal of acquired immune deficiency syndromes, 22 5
-
M.
Lederman,
E.
Connick,
A.
Landay,
D.
Kuritzkes,
J.
Spritzler,
M.
Clair,
B.
Kotzin,
L.
Fox,
Margo
Chiozzi,
J.
Leonard,
F.
Rousseau,
Michael
Wade,
J.
Roe,
Ana
Martínez,
H.
Kessler
(1998)
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
The Journal of infectious diseases, 178 1
-
J.
Angel,
Ajay
Kumar,
K.
Parato,
L.
Filion,
F.
Diaz-Mitoma,
P.
Daftarian,
Ba'
Pham,
E.
Sun,
J.
Leonard,
D.
Cameron
(1998)
Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
The Journal of infectious diseases, 177 4
-
MD
Carpenter,
MD
Cooper,
MD
Fischl,
MD
Gatell,
MA
Gazzard,
MD
Hammer,
MD
Hirsch,
MD
Jacobsen,
BS
Katzenstein,
MD
Montaner,
MD
Richman,
M.
Saag,
MD
Schechter,
PhD
Schooley,
MD
Thompson,
MD
Vella,
MD
Yeni,
MD
Volberding,
MD
CharlesC.J.Car-penter
(2000)
Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel
-
G.
Kaufmann,
M.
Bloch,
J.
Zaunders,
Don
Smith,
D.
Cooper
(2000)
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
AIDS, 14
-
Schlomo
Staszewski,
J.
Morales-Ramirez,
K.
Tashima,
A.
Rachlis,
D.
Skiest,
James
Stanford,
R.
Stryker,
P.
Johnson,
Dominic
Labriola,
Dianne
Farina,
D.
Manion,
N.
Ruiz
(1999)
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
The New England journal of medicine, 341 25
-
A.
Kelleher,
L.
Al-Harthi,
A.
Landay
(1997)
Immunological effects of antiretroviral and immune therapies for HIV.
AIDS, 11 Suppl A
-
M.
Jong,
C.
Boucher,
S.
Danner,
B.
Gazzard,
P.
Griffiths,
C.
Katlama,
J.
Lange,
D.
Richman,
S.
Vella
(1998)
Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections.
Antiviral research, 37 1
-
O.
Cohen,
A.
Kinter,
A.
Fauci
(1997)
Host factors in the pathogenesis of HIV disease
Immunological Reviews, 159
-
M.
Plana,
Felipe
García,
T.
Gallart,
Cecilia
Tortajada,
Á.
Soriano,
E.
Palou,
M.
Maleno,
J.
Barcelo,
C.
Vidal,
A.
Cruceta,
J.
Miro,
J.
Gatell
(2000)
Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection
AIDS, 14
-
G.
Matthews,
C.
Sabin,
S.
Mandalia,
F.
Lampe,
A.
Phillips,
M.
Nelson,
M.
Bower,
M.
Johnson,
B.
Gazzard
(2002)
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
AIDS, 16
-
B.
Autran,
G.
Carcelain
(2000)
Boosting Immunity to HIV--Can the Virus Help?
Science, 290
-
Al
Pozniak
(2000)
Why switch from protease inhibitors (PI) to non‐nucleoside reverse transcriptase inhibitors (NNRTI)?
HIV Medicine, 1
-
A.
Friedl,
B.
Ledergerber,
M.
Flepp,
B.
Hirschel,
A.
Telenti,
H.
Furrer,
H.
Bucher,
E.
Bernasconi,
R.
Weber
(2001)
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study
AIDS, 15
-
T.
Li,
R.
Tubiana,
C.
Katlama,
V.
Calvez,
H.
Mohand,
B.
Autran
(1998)
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
The Lancet, 351
-
(1998)
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals
-
F.
Martinon,
C.
Michelet,
I.
Peguillet,
Y.
Taoufik,
P.
Lefebvre,
C.
Goujard,
J.
Guillet,
J.
Delfraissy,
O.
Lantz
(1999)
Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy.
AIDS, 13 2
-
G.
Shearer,
M.
Clerici
(1998)
Cytokine profiles in HIV type 1 disease and protection.
AIDS research and human retroviruses, 14 Suppl 2
-
N.
Pakker,
M.
Roos,
R.
Leeuwen,
M.
Jong,
M.
Koot,
P.
Reiss,
J.
Lange,
F.
Miedema,
S.
Danner,
P.
Schellekens
(1997)
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 16 5
-
Gene
Shearer
(1998)
HIV-induced immunopathogenesis.
Immunity, 9 5
-
J.
Blankson,
J.
Gallant,
R.
Siliciano
(2001)
Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution.
The Journal of infectious diseases, 183 4
-
D.
Winslow,
S.
Garber,
C.
Reid,
H.
Scarnati,
D.
Baker,
M.
Rayner,
E.
Anton
(1996)
Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.
AIDS, 10 11
-
G.
Pialoux,
F.
Raffi,
F.
Brun-vezinet,
V.
Meiffrédy,
P.
Flandre,
J.
Gastaut,
P.
Dellamonica,
P.
Yeni,
J.
Delfraissy,
J.
Aboulker
(1998)
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
The New England journal of medicine, 339 18
-
D.
Richman
(1996)
HIV Therapeutics
Science, 272
-
D.
Emilie,
M.
Maillot,
Jean-François
Nicolas,
R.
Fior,
P.
Galanaud
(1992)
Antagonistic effect of interferon-gamma on tat-induced transactivation of HIV long terminal repeat.
The Journal of biological chemistry, 267 29
-
J.
Lazdins,
M.
Grell,
M.
Walker,
K.
Woods-Cook,
P.
Scheurich,
K.
Pfizenmaier
(1997)
Membrane Tumor Necrosis Factor (TNF) Induced Cooperative Signaling of TNFR60 and TNFR80 Favors Induction of Cell Death Rather Than Virus Production in HIV-infected T Cells
The Journal of Experimental Medicine, 185
-
B.
Autran,
G.
Carcelain,
T.
Li,
C.
Blanc,
D.
Mathez,
R.
Tubiana,
C.
Katlama,
P.
Debré,
J.
Leibowitch
(1997)
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
Science, 277 5322
-
A.
Seth,
J.
Markee,
A.
Hoering,
A.
Sevin,
D.
Sabath,
J.
Schmitz,
M.
Kuroda,
M.
Lifton,
M.
Hirsch,
A.
Collier,
N.
Letvin,
M.
McElrath
(2001)
Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.
The Journal of infectious diseases, 183 5
-
M.
Clerici,
A.
Sarin,
J.
Berzofsky,
A.
Landay,
H.
Kessler,
Farah
Hashemi,
C.
Hendrix,
S.
Blatt,
J.
Rusnak,
M.
Dolan,
R.
Coffman,
P.
Henkart,
G.
Shearer
(1996)
Antigen‐stimulated apoptotic T‐cell death in HIV infection is selective for CD4+T cells, modulated by cytokines and effected by lymphotoxin
AIDS, 10
-
A.
Kelleher,
A.
Carr,
J.
Zaunders,
D.
Cooper
(1996)
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
The Journal of infectious diseases, 173 2
-
J.
Casado,
K.
Hertogs,
L.
Ruíz,
F.
Dronda,
A.
Cauwenberge,
A.
Arnó,
I.
García-Arata,
S.
Bloor,
A.
Bonjoch,
J.
Blázquez,
B.
Clotet,
B.
Larder
(2000)
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
AIDS, 14
-
R.
Torres,
P.
Bellman,
M.
Barr
(1998)
Amsterdam Duration of Antiretroviral Medication (ADAM) study
The Lancet, 352
-
(2001)
Webb for the Swiss HIV Cohort Study
-
(2002)
Cytokine-specific mRNA in HIV-infected patients undergoing a rescue therapy Time point Cytokine-specific mRNA (cytokine/ -actin ratio) for: IL-4 IL-10
-
M.
Saag,
M.
Holodniy,
D.
Kuritzkes,
W.
O'brien,
R.
Coombs,
M.
Poscher,
D.
Jacobsen,
G.
Shaw,
D.
Richman,
P.
Volberding
(1996)
HIV viral load markers in clinical practice
Nature Medicine, 2
-
Oscar
Pontesilli,
S.
Kerkhof-Garde,
D.
Notermans,
Norbert
Foudraine,
M.
Roos,
M.
Klein,
S.
Danner,
J.
Lange,
Frank
Miedema
(1999)
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.
The Journal of infectious diseases, 180 1
-
M.
Clerici,
N.
Stocks,
R.
Zajac,
R.
Boswell,
Denise
Bernstein,
Dean
Mann,
Gene
Shearer,
J.
Berzofsky
(1989)
Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals
Nature, 339
-
A.
Carr,
D.
Cooper
(1996)
HIV protease inhibitors
AIDS, 10
-
M.
Clerici,
E.
Seminari,
F.
Suter,
F.
Castelli,
A.
Pan,
M.
Biasin,
F.
Colombo,
D.
Trabattoni,
F.
Maggiolo,
G.
Carosi,
R.
Maserati
(2000)
Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia
AIDS, 14